273 related articles for article (PubMed ID: 18426405)
41. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility.
Schmierer B; Hill CS
Nat Rev Mol Cell Biol; 2007 Dec; 8(12):970-82. PubMed ID: 18000526
[TBL] [Abstract][Full Text] [Related]
42. [TGF-beta signaling during bone metastasis of breast cancer and in-vivo imaging].
Imamura T; Hanyu A
Clin Calcium; 2008 Apr; 18(4):460-5. PubMed ID: 18379027
[TBL] [Abstract][Full Text] [Related]
43. Overlapping activities of TGF-β and Hedgehog signaling in cancer: therapeutic targets for cancer treatment.
Perrot CY; Javelaud D; Mauviel A
Pharmacol Ther; 2013 Feb; 137(2):183-99. PubMed ID: 23063491
[TBL] [Abstract][Full Text] [Related]
44. The role of transforming growth factor-beta in atherosclerosis.
Singh NN; Ramji DP
Cytokine Growth Factor Rev; 2006 Dec; 17(6):487-99. PubMed ID: 17056295
[TBL] [Abstract][Full Text] [Related]
45. Development of TGF-beta signalling inhibitors for cancer therapy.
Yingling JM; Blanchard KL; Sawyer JS
Nat Rev Drug Discov; 2004 Dec; 3(12):1011-22. PubMed ID: 15573100
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of TGFβ signaling and its implications in anticancer treatments.
Calone I; Souchelnytskyi S
Exp Oncol; 2012; 34(1):9-16. PubMed ID: 22453142
[TBL] [Abstract][Full Text] [Related]
47. Context-dependent regulation of cutaneous immunological responses by TGFbeta1 and its role in skin carcinogenesis.
Glick AB; Perez-Lorenzo R; Mohammed J
Carcinogenesis; 2008 Jan; 29(1):9-14. PubMed ID: 17893229
[TBL] [Abstract][Full Text] [Related]
48. [Mechanism of transforming growth factor beta/Smad signaling and the relationship between its transduction and liver fibrosis].
Li YR; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2005 Jun; 13(6):476-8. PubMed ID: 15975296
[No Abstract] [Full Text] [Related]
49. The soluble transforming growth factor-beta receptor: advantages and applications.
Russo LM; Brown D; Lin HY
Int J Biochem Cell Biol; 2009 Mar; 41(3):472-6. PubMed ID: 18339576
[TBL] [Abstract][Full Text] [Related]
50. Transforming growth factor-beta pathway: role in pancreas development and pancreatic disease.
Rane SG; Lee JH; Lin HM
Cytokine Growth Factor Rev; 2006; 17(1-2):107-19. PubMed ID: 16257256
[TBL] [Abstract][Full Text] [Related]
51. Transforming growth factor-beta: a target for cancer therapy.
Kelly RJ; Morris JC
J Immunotoxicol; 2010 Mar; 7(1):15-26. PubMed ID: 19916703
[TBL] [Abstract][Full Text] [Related]
52. Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance.
Campioni M; Santini D; Tonini G; Murace R; Dragonetti E; Spugnini EP; Baldi A
Exp Dermatol; 2005 Nov; 14(11):811-8. PubMed ID: 16232302
[TBL] [Abstract][Full Text] [Related]
53. Role of TGF-β in melanoma.
Busse A; Keilholz U
Curr Pharm Biotechnol; 2011 Dec; 12(12):2165-75. PubMed ID: 21619542
[TBL] [Abstract][Full Text] [Related]
54. Protein kinase C in melanoma.
Oka M; Kikkawa U
Cancer Metastasis Rev; 2005 Jun; 24(2):287-300. PubMed ID: 15986138
[TBL] [Abstract][Full Text] [Related]
55. Targeting the stromal fibroblasts: a novel approach to melanoma therapy.
Smalley KS; Lioni M; Herlyn M
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1069-78. PubMed ID: 16336098
[TBL] [Abstract][Full Text] [Related]
56. Targeting TGF-β Signaling in Cancer.
Colak S; Ten Dijke P
Trends Cancer; 2017 Jan; 3(1):56-71. PubMed ID: 28718426
[TBL] [Abstract][Full Text] [Related]
57. Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression.
Jones E; Pu H; Kyprianou N
Expert Opin Ther Targets; 2009 Feb; 13(2):227-34. PubMed ID: 19236240
[TBL] [Abstract][Full Text] [Related]
58. A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment.
Huynh LK; Hipolito CJ; Ten Dijke P
Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31744193
[TBL] [Abstract][Full Text] [Related]
59. TGF-β may control the switch between tumorigenic growth and "stem cell/mesenchymal" potentially drug-resistant states.
Bordelon JR; Grichnik JM
Dermatol Ther; 2015; 28(3):177-8. PubMed ID: 25649199
[No Abstract] [Full Text] [Related]
60. The new arms race against melanoma.
Lejeune FJ
Melanoma Res; 2006 Feb; 16(1):1-2. PubMed ID: 16432449
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
